Related references
Note: Only part of the references are listed.Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol
J. Stutterheim et al.
EUROPEAN JOURNAL OF CANCER (2022)
Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial
Erin M. Guest et al.
HAEMATOLOGICA (2022)
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
Janine Stutterheim et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol
Grigory Tsaur et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631
Patrick A. Brown et al.
LEUKEMIA (2021)
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial
Daisuke Tomizawa et al.
BLOOD (2020)
Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols
Alexander Popov et al.
LEUKEMIA (2020)
How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?
Xueyan Chen et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment
C. Eckert et al.
LEUKEMIA (2015)
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008
M. Brueggemann et al.
LEUKEMIA (2010)
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
V. H. J. Van der Velden et al.
LEUKEMIA (2009)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Michael J. Borowitz et al.
BLOOD (2008)
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
E Coustan-Smith et al.
BLOOD (2000)